S&P Futures
4,528.50 -8.00 (-0.18%) Dow Futures
35,489.00 -68.00 (-0.19%) Nasdaq Futures
15,320.00 -21.00 (-0.14%) Russell 2000 Futures
2,282.30 -6.50 (-0.28%) Crude Oil
83.98 +0.22 (+0.26%) Gold
1,794.20 -2.10 (-0.12%)
Tetra Bio-Pharma Inc. (TBP.TO)
Chart Events
Performance Outlook
| Previous Close | 0.2350 |
| Open | 0.2300 |
| Bid | 0.2250 x N/A |
| Ask | 0.2300 x N/A |
| Day's Range | 0.2200 - 0.2350 |
| 52 Week Range | 0.1450 - 0.5300 |
| Volume | 781,780 |
| Avg. Volume | 468,590 |
| Market Cap | 90.375M |
| Beta (5Y Monthly) | 2.14 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1000 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
- CNW Group
Tetra Bio-Pharma Receives Positive Opinion for Orphan Drug Designation for QIXLEEF™ from the European Medicines Agency
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) issued a positive opinion on the Company's application for Orphan Drug Designation (ODD) for its investigational medicine QIXLEEF™ as a potential treatment for Complex Regional Pain Syndrome (CRPS), a chronic neuropathic pain condition.
- PR Newswire
Tetra Bio-Pharma Provides Update on Clinical Development Program for QIXLEEF™
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development today provided an update on the progress and significant achievements of its lead investigational drug, QIXLEEF™.
- PR Newswire
REDUVO™ - A Major Milestone for Tetra Bio-Pharma Inc.
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announced today that numerous pre-launch activities for REDUVO™ have been initiated. REDUVO™ is a cannabinoid-derived drug indicated in chemotherapy-induced nausea and vomiting (CINV). In December 2020, the Company submitted a New Drug Submission to Health Canada which is currently in its final stage of review by the regulator.
